LOGIN
Therapeutic response in OA per OMERACT-OARSI criteria better with etoricoxib than placebo
April 2013
Therapeutic response in OA per OMERACT-OARSI criteria better with etoricoxib than placebo
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A
Responder analysis and correlation of outcome measures: pooled results from two identical studies comparing etoricoxib, celecoxib, and placebo in osteoarthritis
Osteoarthritis Cartilage. 2008 Nov;16(11):1289-93. Epub 2008 Jun 2Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
1207 patients with severe osteoarthritis (OA) of the hip or knee were randomized in two parallel studies to receive etoricoxib or celecoxib or placebo for a period of 12 weeks. At the study conclusion, the treatment of OA with etoricoxib or celecoxib had a better clinical response according to the OMERACT-OARSI criteria than the placebo treatment.
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.